Enabling Technologies for MRI-Guided Prostate Interventions

MRI 引导前列腺干预的支持技术

• 批准号: 7253977
• 负责人: CLARE M TEMPANY
• 金额: $ 72.72万
• 依托单位: BRIGHAM AND WOMEN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-07-01 至 2011-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7253977
• 关键词: Acute; Adherence; Agreement; Anatomic Models; Anatomy; Anogenital region; Architecture; Area; Biomedical Engineering; Biopsy; Brachytherapy; Brachytherapy Seeds; Caring; Clinical; Cold Therapy; Compatible; Computer software; Conduct Clinical Trials; Data; Development; Devices; Diagnosis; Diagnostic; Dose-Rate; Elements; Engineering; Environment; Focused Ultrasound Therapy; Funding; Future; Goals; Government; Grant; Hospitals; Hour; Human; Image; Image Analysis; Imagery; Imaging Device; Imaging Techniques; Implant; Industry; Institution; Intervention; Lead; Lesion; Living Wills; Local Therapy; Magnetic Resonance Imaging; Malignant Neoplasms; Malignant neoplasm of prostate; Mechanics; Medical; Methodology; Methods; Modality; Modeling; Monitor; Motion; NIH Program Announcements; Needle biopsy procedure; Needles; Optical Tomography; Optics; Other Imaging Modalities; Outcome; PET/CT scan; Patients; Physicians; Physiological; Placement; Planning Techniques; Pliability; Procedures; Process; Production; Prostate; Prostatic; Protocols documentation; Publications; Purpose; Quality of life; Range; Regulation; Relative (related person); Research; Research Personnel; Robot; Robotics; Safety; Seed Implantation; Seeds; Sensitivity and Specificity; Skin; Software Tools; Specificity; Spectrum Analysis; Speed; Structure; Study Section; System; Systems Integration; Techniques; Technology; Testing; Therapeutic; Therapeutic procedure; Time; Tissues; Toxic effect; Translating; Transrectal Ultrasound; Treatment Protocols; Ultrasonography; United States Food and Drug Administration; United States National Institutes of Health; Universities; Vendor; Woman; base; cancer care; cancer therapy; design; dosimetry; image guided intervention; image processing; imaging probe; improved; interest; magnetic field; men; microwave electromagnetic radiation; molecular imaging; multidisciplinary; novel; portability; programs; prototype; radiofrequency; research clinical testing; tool

DESCRIPTION (provided by applicant): MRI is an ideal imaging tool for guiding and monitoring prostate cancer biopsy and local therapy. The high sensitivity and specificity to focal prostate lesions and abnormalities, combined with real-time monitoring of the delivery process and subsequent physiological changes hold great potentials. Unfortunately, closed high-field MRI scanners, the most superior imaging systems, have been unavailable for interventions. The strong magnetic field and confined physical space present formidable challenges, and "conventional" difficulties such as needle deflection, tissue deformation, and target motion add to the problem. Our teams have established the clinical and technical feasibility for MRI-guided prostate biopsy and therapy. We are proposing to translate this technology outside the confines of our specialized research hospitals. In particular, we will develop a technology platform for precise trans-perineal needle placement into the prostate for both diagnostic and therapeutic purposes; inside conventional (high-field closed) MRI scanners, under real-time image guidance and monitoring. This system will be uniformly applicable to'a wide range of MRI scanners, supporting long bore, short bore, and open magnets of high and low fields alike. The initial applications will be prostate biopsy and low-dose-rate Brachytherapy. This system will be robust, simple, and operable by a multi-disciplinary team of physicians. Toward this goal, we propose a BRP between the Brigham and Women's Hospital, Johns Hopkins University, and CMS Image Guidance Division (formerly Burdette Medical). Our teams have complimentary strengths in MR guided interventions, robotics, and prostate cancer treatment with intraoperative dosimetry. A research triangle has been in de-facto existence for several years and produced shared technology, publications, and inventions; supported by government grants. The Brigham group established the clinical feasibility of MR guided transperineal prostate biopsy and brachytherapy, funded by RO1-5R01AG019513-03 (PI Tempany). The Hopkins team created an in-MRI prostate robot currently in human trials for biopsy and seed placement, co-funded by R01-EB002963-01 (PI: Fichtinger). The Burdette group developed a commercial prostate cancer brachytherapy suite with over 60 installations worldwide, co-funded by NIH grants 5R44CA088139-04 and 1R43CA099374-01 (PI: Burdette). Strong results, multidisciplinary expertise, and existing partnerships support our proposal.

描述（由申请人提供）：MRI 是指导和监测前列腺癌活检和局部治疗的理想成像工具。对局灶性前列腺病变和异常的高敏感性和特异性，加上对输送过程和随后的生理变化的实时监测，具有巨大的潜力。不幸的是，封闭式高场核磁共振扫描仪（最先进的成像系统）无法用于干预。强磁场和有限的物理空间带来了巨大的挑战，而针偏转、组织变形和目标运动等“传统”困难则加剧了问题。我们的团队已经确定了 MRI 引导的前列腺活检和治疗的临床和技术可行性。我们建议将这项技术推广到我们专业研究医院的范围之外。特别是，我们将开发一个技术平台，用于将经会阴针精确置入前列腺，用于诊断和治疗目的；在传统（高场封闭）MRI 扫描仪内部，在实时图像引导和监控下。该系统将统一适用于各种 MRI 扫描仪，支持长孔、短孔以及高磁场和低磁场的开放磁体。最初的应用将是前列腺活检和低剂量近距离放射治疗。该系统将是强大的、简单的，并且可以由多学科的医生团队操作。为了实现这一目标，我们提议在布莱根妇女医院、约翰·霍普金斯大学和 CMS 图像指导部门（以前称为 Burdette Medical）之间建立 BRP。我们的团队在 MR 引导干预、机器人技术和术中剂量测定前列腺癌治疗方面拥有互补优势。研究三角实际上已存在多年，并产生了共享技术、出版物和发明；得到政府补助的支持。 Brigham 小组确立了 MR 引导经会阴前列腺活检和近距离放射治疗的临床可行性，由 RO1-5R01AG019513-03 (PI Tempany) 资助。霍普金斯大学团队创建了一种 MRI 前列腺机器人，目前正在进行用于活检和种子放置的人体试验，由 R01-EB002963-01（PI：Fichtinger）共同资助。 Burdette 小组开发了一套商业前列腺癌近距离放射治疗套件，在全球安装了 60 多个装置，由 NIH 拨款 5R44CA088139-04 和 1R43CA099374-01（PI：Burdette）共同资助。强劲的成果、多学科专业知识和现有的合作伙伴关系支持我们的建议。